Register Login

EDESA BIOTECH, INC. (EDSA)

SymbolEDSA
NameEDESA BIOTECH, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address100 SPY COURT, MARKHAM, Ontario, L3R 5H6, Canada
Telephone+1 905 475-1234
Fax—
Email—
Websitehttps://www.edesabiotech.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001540159
Description

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The companys product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The companys EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Additional info from NASDAQ:
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The companys product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The companys EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

2026-07-02 21:05

Director Nijhawan Pardeep 🟢 acquired 3.4K shares of Edesa Biotech, Inc. (EDSA) Transaction Date: Jul 02, 2026 | Filing ID: 004451

Read more
2026-07-02 18:01

New Form S-3 - Edesa Biotech, Inc. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001171843-26-004449 <b>Size:</b> 409 KB

Read more
2026-06-26 18:05

New Form D - Edesa Biotech, Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001493152-26-030335 <b>Size:</b> 11 KB

Read more
2026-06-16 21:03

Director Nijhawan Pardeep 🟢 acquired 153.6K shares of Edesa Biotech, Inc. (EDSA) at $5.21 Transaction Date: Jun 16, 2026 | Filing ID: 004151

Read more
2026-06-16 18:07

New Form SCHEDULE 13D/A - Edesa Biotech, Inc. <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0001171843-26-004153 <b>Size:</b> 21 KB

Read more
2026-06-11 13:20

(70% Positive) EDESA BIOTECH, INC. (EDSA) Provides Update on result for immuno-inflammatory diseases

Read more
2026-06-11 13:15

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Read more
2026-06-05 13:25

(85% Positive) EDESA BIOTECH, INC. (EDSA) Announces Clinical Development Update

Read more
2026-06-05 13:20

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Read more
2026-05-29 21:02

Director Marshall Patrick 🟢 acquired 19.0K shares of Edesa Biotech, Inc. (EDSA) Transaction Date: May 27, 2026 | Filing ID: 003805

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06701656 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Beva… Phase2 Acute Respiratory Distress Syndrome (ARDS) Recruiting 2025-10-28 2028-09-01 ClinicalTrials.gov
NCT06701682 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilo… Phase2 Acute Respiratory Distress Syndrome (ARDS) Recruiting 2025-06-21 2028-09-01 ClinicalTrials.gov
NCT06703073 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) Phase2 Acute Respiratory Distress Syndrome (ARDS) Recruiting 2025-06-10 2028-09-01 ClinicalTrials.gov
NCT06701669 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Pari… Phase2 Acute Respiratory Distress Syndrome (ARDS) Recruiting 2025-06-10 2028-09-01 ClinicalTrials.gov
NCT04401475 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and… Phase2 COVID-19 Suspended 2020-11-25 2024-12-01 ClinicalTrials.gov
NCT03680131 Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatit… Phase2 Allergic Contact Dermatitis Completed 2019-10-15 2023-01-17 ClinicalTrials.gov
Total clinical trials: 6
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
SOC plus Placebo IV Other Phase PHASE2 COVID-19 SUSPENDED NCT04401475
SOC plus 15mg/kg EB05 IV Other Phase PHASE2 COVID-19 SUSPENDED NCT04401475
EB01 Cream 2.0% Other Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream 1.0% Other Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream 0.2% Other Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream Placebo Other Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort A: vilobelimab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701682
Cohort B: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort B: paridiprubart Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701669
Cohort C: placebo Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort C: bevacizumab Other Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06701656
Cohort A: placebo DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort A: vilobelimab DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: placebo DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort B: paridiprubart DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: placebo DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
Cohort C: bevacizumab DRUG Phase PHASE2 Acute Respiratory Distress Syndrome (ARDS) RECRUITING NCT06703073
SOC plus Placebo IV OTHER Phase PHASE2 COVID-19 SUSPENDED NCT04401475
SOC plus 15mg/kg EB05 IV BIOLOGICAL Phase PHASE2 COVID-19 SUSPENDED NCT04401475
EB01 Cream 2.0% DRUG Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream 1.0% DRUG Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream 0.2% DRUG Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
EB01 Cream Placebo DRUG Phase PHASE2 Allergic Contact Dermatitis COMPLETED NCT03680131
Total products: 96